NYSEAMERICAN:PLX - Protalix Biotherapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.4750 0.00 (0.00 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$0.4750
Today's Range$0.45 - $0.4829
52-Week Range$0.38 - $0.92
Volume365,417 shs
Average Volume701,094 shs
Market Capitalization$308.37 million
P/E RatioN/A
Dividend YieldN/A
Beta0.97
Protalix Biotherapeutics logoProtalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.

Receive PLX News and Ratings via Email

Sign-up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:PLX
CUSIPN/A
Phone+972-4-9028100

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares148,180,000
Market Cap$308.37 million

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

How were Protalix Biotherapeutics' earnings last quarter?

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) released its earnings results on Thursday, August, 9th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.03. The company had revenue of $2.01 million for the quarter, compared to analyst estimates of $7 million. View Protalix Biotherapeutics' Earnings History.

When is Protalix Biotherapeutics' next earnings date?

Protalix Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Protalix Biotherapeutics.

What price target have analysts set for PLX?

1 equities research analysts have issued 1 year target prices for Protalix Biotherapeutics' shares. Their predictions range from $4.00 to $4.00. On average, they anticipate Protalix Biotherapeutics' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 742.1% from the stock's current price. View Analyst Price Targets for Protalix Biotherapeutics.

What is the consensus analysts' recommendation for Protalix Biotherapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protalix Biotherapeutics.

What are Wall Street analysts saying about Protalix Biotherapeutics stock?

Here are some recent quotes from research analysts about Protalix Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. " (8/15/2018)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our model yields an rNPV of $213M for PRX-102 using a 15% discount rate and 75% probability of approval, accounting for the Chiesi partnership and receipt of royalties on PRX-102 sales globally." (8/13/2018)

Are investors shorting Protalix Biotherapeutics?

Protalix Biotherapeutics saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 1,987,733 shares, a decrease of 20.6% from the July 13th total of 2,504,181 shares. Based on an average daily volume of 1,154,263 shares, the days-to-cover ratio is presently 1.7 days. Currently, 1.5% of the company's stock are sold short. View Protalix Biotherapeutics' Current Options Chain.

Who are some of Protalix Biotherapeutics' key competitors?

Who are Protalix Biotherapeutics' key executives?

Protalix Biotherapeutics' management team includes the folowing people:
  • Mr. Moshe Manor, Chief Exec. Officer, Pres and Director (Age 62)
  • Dr. Yoseph Shaaltiel Ph.D., Founder and Exec. VP of R&D (Age 64)
  • Mr. Yossi Maimon CPA, MBA, Chief Financial Officer, VP, Treasurer and Sec. (Age 47)
  • Dr. Einat Brill-Almon Ph.D., Sr. VP of Product Devel. (Age 58)
  • Mr. Tzvi Palash, Exec. Officer (Age 61)

Has Protalix Biotherapeutics been receiving favorable news coverage?

News articles about PLX stock have been trending somewhat positive on Saturday, Accern reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Protalix Biotherapeutics earned a daily sentiment score of 0.12 on Accern's scale. They also gave news articles about the company an impact score of 45.69 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Protalix Biotherapeutics.

Who are Protalix Biotherapeutics' major shareholders?

Protalix Biotherapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Opaleye Management Inc. (2.13%) and Renaissance Technologies LLC (1.80%). Company insiders that own Protalix Biotherapeutics stock include Camber Capital Management Llc, Madalena Energy Inc, Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Institutional Ownership Trends for Protalix Biotherapeutics.

Which major investors are selling Protalix Biotherapeutics stock?

PLX stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc.. View Insider Buying and Selling for Protalix Biotherapeutics.

Which major investors are buying Protalix Biotherapeutics stock?

PLX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Protalix Biotherapeutics stock in the last two years include Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Insider Buying and Selling for Protalix Biotherapeutics.

How do I buy shares of Protalix Biotherapeutics?

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protalix Biotherapeutics' stock price today?

One share of PLX stock can currently be purchased for approximately $0.4750.

How big of a company is Protalix Biotherapeutics?

Protalix Biotherapeutics has a market capitalization of $308.37 million.

How can I contact Protalix Biotherapeutics?

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.


MarketBeat Community Rating for Protalix Biotherapeutics (NYSEAMERICAN PLX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  110 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  221
MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe PLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Featured Article: Asset Allocation

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.